CAJ | 학술논문

目的：探讨艾迪注射液联合多西他赛、卡铂方案对非小细胞肺癌的临床疗效及血清鳞状细胞癌相关抗原（SCC-Ag）、细胞角蛋白19片段（CYFRA21-1）、癌胚抗原（CEA）水平的影响。方法将64例非小细胞肺癌患者随机分为试验组32例和对照组32例，对照组采用多西他赛、卡铂方案，试验组在对照组基础上联合艾迪注射液；比较两组患者临床疗效、生存质量、不良反应发生情况及两组患者治疗前后血清SCC-Ag、CY-FRA21-1、CEA的变化水平。结果试验组和对照组的总有效率分别为31.25%和28.13%，差异无统计学意义（χ2=0.233，P=0.629），试验组的临床获益率为93.75%，显著高于对照组的84.38%，两组间差异具有统计学意义（χ2=4.507，P=0.034）。试验组治疗后生理功能、情感功能、社会功能得分显著提高、疲劳、疼痛，恶心呕吐得分显著降低，与对照组相比差异具有统计学意义（P＜0.05）；试验组白细胞减少发生率显著低于对照组（χ2=9.374，P=0.002）。试验组治疗后的血清SCC-Ag、CYFRA21-1、CEA水平均显著降低，与治疗前及与对照组治疗后相比差异均具有统计学意义（P＜0.05）。结论艾迪注射液能够提高非小细胞肺癌患者生存质量，降低不良反应发生，可以作为非小细胞肺癌化疗的辅助用药。
목적：탐토애적주사액연합다서타새、잡박방안대비소세포폐암적림상료효급혈청린상세포암상관항원（SCC-Ag）、세포각단백19편단（CYFRA21-1）、암배항원（CEA）수평적영향。방법장64례비소세포폐암환자수궤분위시험조32례화대조조32례，대조조채용다서타새、잡박방안，시험조재대조조기출상연합애적주사액；비교량조환자림상료효、생존질량、불량반응발생정황급량조환자치료전후혈청SCC-Ag、CY-FRA21-1、CEA적변화수평。결과시험조화대조조적총유효솔분별위31.25%화28.13%，차이무통계학의의（χ2=0.233，P=0.629），시험조적림상획익솔위93.75%，현저고우대조조적84.38%，량조간차이구유통계학의의（χ2=4.507，P=0.034）。시험조치료후생리공능、정감공능、사회공능득분현저제고、피로、동통，악심구토득분현저강저，여대조조상비차이구유통계학의의（P＜0.05）；시험조백세포감소발생솔현저저우대조조（χ2=9.374，P=0.002）。시험조치료후적혈청SCC-Ag、CYFRA21-1、CEA수평균현저강저，여치료전급여대조조치료후상비차이균구유통계학의의（P＜0.05）。결론애적주사액능구제고비소세포폐암환자생존질량，강저불량반응발생，가이작위비소세포폐암화료적보조용약。
Objective To explore the clinical efficacy and the impact on serum squamous cell carcinoma antigen (SCC-Ag), cytokeratin 19 fragment (CYFRA21-1), and carcinoembryonic antigen (CEA) level of Addie injection combined with docetaxel and carboplatin in non-small cell lung cancer (NSCLC) patients. Method 64 cases of NSCLC were randomized into experimental group (32 cases) or control group (32 cases), and the control group was administered with docetaxel and carboplatin, based on which the experimental group was additionally combined with Addie injection. The clinical efficacy, quality of life (QOL) and adverse reactions (AE), as well as pre-treatment and post-treatment serum SCC-Ag, CYFRA21-1, CEA levels of both groups were compared. Result The overall re-sponse rate of experimental group and control group was 31.25% and 28.13%, with no significant differences ob-served (χ2=0.233, P=0.629); while the clinical benefit rate was significantly higher in experimental group than con-trol group (93.75% vs 84.38%, χ2=4.507 ,P=0.034). The physiological function, emotional function and social func-tion scores improved significantly in experimental group, while the fatigue, pain, nausea and vomiting scores signifi-cantly decreased, and the differences of which were of significance when compared with the control group (P<0.05). As for AE, the incidence of leukopenia in experimental group was lower than control group (χ2=9.374, P=0.002). The post-treatment serum SCC-Ag, CYFRA21-1 and CEA levels in experimental group were decreased significantly, and were still lower when compared with control group after treatment (P<0.05). Conclusion Addie injection im-proves the quality of life of patients with NSCLC, as well as reduces adverse reaction, for which it is qualified as important adjuvant chemotherapy in non-small cell lung cancer.